Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.Frank M. Speetjens,Marij J. P. Welters,Marije Slingerland,Peggy de Vos van Steenwijk,Inge C. F. M. Roozen,Sanne Boekestijn,Nikki Loof,Gijs G. Zom,Rob Valentijn,Willem-Jan Krebber,Cornelis J. M. Melief,Dmitri V. Filippov,Hans Gelderblom,Sjoerd H. van der Burg,Ferry OssendorpJOURNAL OF CLINICAL ONCOLOGY（2021）引用 3|浏览11暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
